Elucidating the precise pharmacological mechanism of motion (MOA) of naturally developing compounds may be challenging. Although Tarselli et al. (sixty) developed the initial de novo synthetic pathway to conolidine and showcased this naturally taking place compound correctly suppresses responses to both of those chemically induced and inflammation-